The importance of whey protein levels of Klotho and fibroblast growth of factor-23 (fgf-23) as early diagnostic markers of chronic kidney damage
摘要
The purpose of the study is to investigate the clinical significance of determination of serum FGF-23 and Klotho in patients with different stages of chronic kidney disease (CKD). Materials and Methods: The study included 70 patients with CKD stages 1–5D (30 men and 40 women, mean age 41,0–6,7 years), in whom the serum levels of FGF-23 and Klotho, as well as work Ca х P and the content of intact parathyroid hormone (iPTH). Results: the progression of CKD from stage 1 to 5D serum concentration of FGF-23 was increased, and the concentration of Klotho decreased. Glomerular filtration rate (GFR) was directly correlated with the serum concentration of FGF-23 (r=0,693, p <0,01) and back — with a protein concentration of Klotho (r=-0,799, p <0,01). Increased levels of FGF- 23 as GFR decline began in CKD stage 3 and outpaced the increase in serum levels of phosphorus and iPTH, which increased in CKD stage 4–5. In 49 patients with CKD and hypertension increase the degree of BP directly correlated with the serum concentration of FGF-23 (r=0,452; p <0,01) and back — with the serum concentration of Klotho (r=-0,687; p <0,01). In addition, changes in the levels found a link of FGF-23 and Klotho with increasing thickness of the posterior wall of the left ventricle, the frequency of detection of calcifications in the heart and major arteries and anemia. Conclusion: These results suggest the possibility of practical application of Klotho and FGF-23 levels as an early diagnostic marker of kidney damage for prognosis and improve cardio-renoprotective strategies.
关于作者
L. Milovanova
I.M. Sechenov First MSMU
俄罗斯联邦
俄罗斯联邦
S. Milovanova
I.M. Sechenov First MSMU
俄罗斯联邦
俄罗斯联邦
D. Kryukova
M.V. Lomonosov MSU
俄罗斯联邦
俄罗斯联邦
S. Moiseev
I.M. Sechenov First MSMU
俄罗斯联邦
俄罗斯联邦
L. Kozlovskaya
I.M. Sechenov First MSMU
俄罗斯联邦
俄罗斯联邦
参考
1. Sarnak M. Cardiovascular complications in chronic kidney disease // Am. J. Kidney Dis., 2003, 41, 11-17.
2. Hruska K., Mathew S., Lund R. Hyperphosphatemia of chronic kidney disease // Kidney Int., 2008, 74 (2), 148–157.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evalution, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKDMBD) // Kidney Int., 2009, 76 (Suppl. 113), S1-S130.
4. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек. Российское диализное общество (май 2010) // Нефрол. диализ, 2011, 13 (1), 33-51.
5. Gutierrez O., Isakova T., Rhee E. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol defi ciency in chronic kidney disease // Am. J. Soc. Nephrol., 2005, 16, 2205–2215.
6. Chung-Yi C., Makoto K., Razzaque M. Molecular regulation of phosphate metabolism by fi broblast growth factor-23–Klotho system // Adv. Chronic Kidney Dis., 2011, 18 (2), 91–97.
7. Hu M., Shi M., Zhang J. et al. Klotho defi ciency causes vascular calcifi cation in chronic kidney disease // Am. J. Soc. Nephrol. 2011, 22 (1), 124-136.
8. Hu P., Xuan Q., Hu B. et al. Fibroblast growth factor-23 helps explain the biphasic cardiovascular eff ects of vitamin D in chronic kidney disease // Biol. J. Sci., 2012, 8 (5), 663–671.
9. Kuro- M. Klotho in chronic kidney disease — what’s new? // Nephrol. Dialysis Transplant., 2009, 24 (6), 1705-1708.
10. Semba R., Cappola A., Sun K. et al. Plasma klotho and cardiovascular disease in adults // Am. J. Geriatr. Soc., 2011, 59 (9), 1596–1601.
11. Maltese G., Karalliedde J. The putative role of the antiageing protein Klotho in cardiovascular and renal disease // Int. J. Hypertens., 2012, 2012, 757469.
12. Martin A., David V., Quarles L. D. Regulation and function of the FGF23/Klotho endocrine pathways // Physiol Rev., 2012, 92 (1), 131–155.
13. Cavalli L., Mazzotta C., Brandi M. Phosphatonins: physiological role and pathological changes // Clin. Cases. Miner. Bone Metab., 2012, 9 (1), 9–12.
14. Milovanova L., Milovanov Y., Plotnikova A. Phosphorus and calcium metabolism disorders assosiated with chronic kidney disease stage III-IV (systematic rewiew and metaanalysis) // Chronic kidney disease and renal transplantation. Ed. Manisha Sahay. INTECH., 2012, 95-118.
15. Шутов Е.В. Значение фактора роста фибробластов-23 у больных хронической болезнью почек — обзор современных исследований // Лечащий врач, 2012, 8, 12-18.
16. Kuro-o M., Matsumura Y., Aizawa H. et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing // Nature, 1997, 390 (6655), 45–51.
17. Добронравов В.А. Cовременный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Klotho // Нефрология, 2011, 15 (4), 11-20.
18. Matsumura Y., Aizawa H., Shiraki-Iida T. et al. Identifi cation of the human Klotho gene and its two transcripts encoding membrane and secreted Klotho protein. Biochem. Biophys // Res. Comm., 1998, 242 (3), 626–630.
19. Gutiйrrez O., Januzzi J., Isakova T. et al. Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney disease // Circulation, 2009, 119 (19), 2545–2552.
20. Hu M., Shi M., Zhang J. et al. Klotho defi ciency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective // Kidney Intern., 2010, 78 (12), 1240–1251.
21. Sugiura H., Yoshida T., Tsuchiya K. et al. Klotho reduces apoptosis in experimental ischaemic acute renal failure // Nephrol. Dialysis Transplant., 2005, 20 (12), 2636–2645.
22. Sugiura H., Yoshida T., Mitobe M. et al. Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70 // Nephrol. Dialysis Transplant., 2010, 25 (1), 60–68.
23. Aizawa H., Saito Y., Nakamura T. et al. Downregulation of the Klotho gene in the kidney under sustained circulatory stress in rats // Biochem. Biophys. Res. Comm., 1998, 249 (3), 865–871.
24. Mirza M., Larsson A., Lind L. et al. Circulating fi broblast growth factor-23 is associated with vascular dysfunction in the community // Atherosclerosis, 2009, 205, 385–390.
25. Maekawa Y., Ishikawa K., Yasuda O. et al. Klotho suppresses TNF-α-induced expression of adhesion molecules in the endothelium and attenuates NF-κB activation // Endocrine, 2009, 35 (3), 341–346.
26. Mitani H., Ishizaka N., Aizawa T. et al. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage // Hypertension, 2002, 39, 838–843.
27. Borst M., Vervloet M. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease // Am. J. Soc. Nephrol., 2011, 22 (9), 1603–1609.
28. Wang Y., Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage // Hypertension, 2009, 54, 810–817.
29. Koh N., Fujimori T., Nishiguchi S. et al. Severely reduced production of Klotho in human chronic renal failure kidney // Biochem. Biophys. Res. Comm., 2001, 280 (4), 1015–1020.
30. Faul C., Amaral A., Oskouei B. et al. FGF23 induces left ventricular hypertrophy // Clin. J. Invest., 2011, 121, 4393–4408.
31. Budoff M., Rader M., Reilly P. et al Relationship of estimated GFR and coronary artery calcifi cation in the (CRIC) Chronic Renal Insuffi ciency Cohort Study // Am. J. Kidney Dis., 2011, 58 (4), 519–526.
32. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis // Semin. Dial., 2003, 16 (2), 101–105.
33. Милованова Л.Ю., Козловская Л.В., Милованов Ю.С., Добросмыслов И.А. Механизмы нарушения фофсорно-кальциевого гомеостаза в развитии сердечно-сосудистых осложнений у больных хронической болезнью почек. Роль фактора роста фибробластов-23 (FGF-23) и Klotho // Тер. архив, 2010, 6, 66-72.
34. Милованова Л.Ю., Милованов Ю.С., Козловская Л.В. Нарушения фосфорно-кальциевого обмена при хронической болезни почек III-V стадий // Клин. нефрология, 2011, 1, 58-68.
35. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С. Гиперфосфатемия как фактор риска сердечно-сосудистых заболеваний у больных ХПН // Нефрол. и диал., 2002, 2, 113-117.
36. Middleton R., Parfrey P., Foley R. Left ventricular hypertrophy in the renal patient // Am. J. Soc. Nephrol., 2001, 12, 1079–1084.
评论
浏览:
373
Email this article 